Neuroimaging tests for clinical psychiatry: Are we there yet?

Marco Leyton, PhD; Sidney H. Kennedy, MD

Biomarkers index normal and abnormal biological processes, sometimes identifying the response potential of particular treatments. Though widely used in much of medicine, none has proven sufficiently robust to enter clinical practice in psychiatry.1,2 And yet, recent high-quality neuroimaging studies give confidence that this is not an unattainable goal. Here’s why.

Neural fingerprinting

There is now replicated evidence of neural “fingerprints.” These functional connectivity networks are unique to the individual and consistent across testing conditions.3,4 In the largest of these studies, with nearly 800 participants tested between the ages of 8 and 22 years, networks stabilized earlier in female than in male participants and earlier in healthy adolescents than psychologically troubled ones.4 Individual differences in these “fingerprints” show evidence of being shaped by early life experiences5,6 and of corresponding to cognitive-affective traits.6,7

Mood

There is now tantalizing evidence that brain connectivity patterns could help predict treatment responses in patients with mood disorders.8–10 In a large multisite study10 with a sample size of more than 1000 patients, 2 configurations were identified. One was characterized by psychomotor retardation and anhedonia linked to altered frontostriatal connectivity and diverse associations with the orbitofrontal cortex. The second was characterized by symptoms of insomnia and anxiety linked to limbic region connectivity (amygdala, hippocampus, ventral striatum, subgenual cingulate, lateral prefrontal cortex). Together these orthogonal clusters yielded 4 “biotypes” that remained stable upon rescanning 4–6 weeks later. These biotypes also predicted treatment responses in a patient subsample (n = 124) that was administered repetitive transcranial magnetic stimulation (rTMS). Though placebo controls were absent, treatment responses ranged from 25% to 83%, with the combination of symptoms plus biotype classifying response with greater than 90% accuracy. When additional functional MRI (fMRI) quality controls were implemented the level of accuracy increased further. Connectome-based strategies have also been applied to other treatment modalities, and distinct subgenual cingulate resting state functional connectivity patterns have been identified in patients (n = 122) who responded to cognitive behavioural therapy versus an antidepressant.11 In each case, the effects were large enough to suggest clinical utility with the promise of benefits to patients and health care services.

Addictions

Altered connectivity patterns12 and regionally specific activations14 have both been tentatively identified in association with addictions. In a meta-analysis of studies measuring responses to monetary reward, differences were observed in people with substance use disorders as compared to healthy volunteers.14 During the reward anticipation phase, arguably a form of secondary conditioning, people with addictions exhibited elevated activations in the amygdala and diminished...
responses in the striatum. During the reward outcome phase (e.g., “You win money!”), considered a complex mix of conditioned and unconditioned reward, people with addictions exhibited augmented responses in the limbic striatum.

It might also be possible to identify markers of future addictions. As found for mood disorders, there is evidence of separable subtypes. In 759 emerging adults (average age 19.6 ± 1.2 years), 2 distinct markers of stress-related problem drinking were identified. One group exhibited elevated threat-induced activations of the amygdala coupled with reduced reward-related activations of the ventral striatum. The second group exhibited the converse pattern: elevated reward-related activations in the ventral striatum and diminished threat-induced activations in the amygdala. The former effects were mediated by anxious-depressive symptoms, while the latter were mediated by delay-discounting impulsivity. We have identified strikingly similar effects. Anxiety-sensitive individuals exhibited elevated amygdalar responses to threat images, and these responses were reduced by alcohol ingestion. In comparison, high sensation-seeking participants exhibited increased stress-induced activations of the medial orbitofrontal cortex and ventral striatum, with the former effect diminished by alcohol ingestion. In both subgroups, prospective follow-up data showed that individual differences in the magnitude of response, specific to each risk group, predicted who transitioned to a substance use problem (M.L., unpublished data, 2017).

The origins of these pathway-specific neurobiological alterations remain unclear, but altered mesocorticolimbic reactivity might include dysregulated dopamine and glutamate transmission. The heightened amygdalar responses in anxious individuals might be potentiated by histories of adverse life experiences and reflect compromised habituation processes when threatening stimuli are presented repeatedly without negative consequences.

Psychoses

Connectivity disturbances have long been hypothesized in patients with schizophrenia, though the particulars were elusive. Now, however, there is replicated evidence that patients with psychotic features exhibit a consistent pattern of reduced global efficiency within the cingulo-opercular salience and subcortical networks (n = 576). Individual differences in network efficiency covaried with cognitive function, with the cortical and the subcortical networks making statistically independent contributions. These findings replicate observations made in 2 separate smaller samples and were presaged by similar findings from independent researchers.

What next?

The excitement generated by these observations should not obscure the challenges ahead. Normative ranges will need to be defined and replicated across different scanners and sites. Care will be required to ensure that the information obtained does not promote prejudicial profiling. And fMRI data are susceptible to movement and other artifacts, raising the possibility that, even if the identified markers prove reliable, they may be unrelated to etiology.

These cautions noted, there is reason for optimism. First, procedures for reducing artifacts are improving rapidly, and the studies described here are of generally high methodological quality (e.g., see Appendix 2, Figure S1 of the study by Drysdale and colleagues). Second, work in other areas of medicine suggests that biomarkers with even greater precision might be constructed from multidimensional indices, including combinations of genes, molecules and systems. For diseases of the brain too, the ability to predict better (or worse) outcomes has been achieved by collating multiple markers, with higher numbers of markers performing better. This strategy might be effective in psychiatry also. Endophenotypes constructed from multiple social, clinical and brain volumetric alterations identified subgroups of patients that crossed diagnoses (n = 1872). The combination of symptoms plus connectivity patterns predicted responses to rTMS better than either feature alone.

As anticipated, the tentatively identified biomarkers do not map on to conventional diagnostic categories. For example, Drysdale and colleagues replicated the anxiety-insomnia-related depression biotype in patients with diagnoses of generalized anxiety disorder. The studies by Sheffield and colleagues found the same psychosis-related connectivity patterns, irrespective of whether the patient’s formal diagnosis was schizophrenia, schizoaffective disorder, or a bipolar mood disorder. Mary Phillips’ research group reports that, in patients with bipolar depression, emotional dysregulation is associated with disturbed connectivity in the limbic circuitry implicated in negative mood states; high sensation-seeking youth exhibit frontostriatal connectivity alterations across diagnoses. Together, this rapidly accumulating body of work suggests that it is no longer incautious to propose that psychiatric biomarkers are within our reach, taking us closer to precision diagnoses, prognoses and treatment.

Affiliations: From the Department of Psychiatry and Psychology, McGill University, Montreal, Que., Canada (Leyton); the Department of Neurology & Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Que., Canada (Leyton); the Center for Studies in Behavioral Neurobiology, Concordia University, Montreal, Que., Canada (Leyton); the Research Unit on Children’s Psychosocial Maladjustment, Université de Montréal, Montreal, Que., Canada (Leyton); the Canadian Biomarker Integration Network for Depression, St. Michael’s Hospital, University Health Network, Toronto, Ont., Canada (Kennedy); and the Department of Psychiatry, University of Toronto, Toronto, Ont., Canada (Kennedy).

Competing interests: M. Leyton declares having received operating funds through his institution from GlaxoSmithKline in 2006–2007 to conduct a study on naloxone. S. Kennedy reports grants from BMS, Janssen, Lundbeck, Pfizer, Servier, St. Jude Medical, the Ontario Brain Institute, Canadian Institutes of Health Research, Brain Canada, the Ontario Mental Health Foundation and the Ontario Research Fund; is on the advisory boards of and has received personal fees from Allergan, AstraZeneca, BMS, Janssen, Lundbeck, Pfizer, Servier, St. Jude Medical and Sunovion; has received speaker fees from Xian-Janssen; and has received research support from Brain Cells Inc and Clera.
References


